Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy

Gaetano Bacci, Cristina Ferrari, Alessandra Longhi, Stefano Ferrari, Cristiana Forni, Patrizia Bacchini, Emanuela Palmerini, Antonio Briccoli, Elettra Pignotti, Alba Balladelli, Piero Picci

Research output: Contribution to journalArticle


We evaluated the rate of second malignancies in 1205 patients with osteosarcoma of the extremity treated at our Institution with different protocols of adjuvant and neoadjuvant chemotherapy. Twenty-six patients (2.15%) developed a second malignant neoplasm at a median of 7.6 years (1 to 25 y) after primary osteosarcoma treatment. Of these, 2 developed a third cancer which were not considered in the series. Second neoplasms were leukemia (10), breast (7), lung (2), kidney (2), central nervous system cancer (2), soft tissue (1), parotid (1), and colon (1). The rate of second neoplasms was significantly higher in female patients, and the latent period shorter in hematologic tumors compared with solid tumors. Ten of these 26 patients are disease free at a median of 7.7 years (range 1 to 15 y) after the last treatment. The rate of second malignancies observed in the osteosarcoma group was significantly higher than that observed in the control group of 1160 patients with benign tumors treated in the same period at our Institute (2.2% vs. 0.8%, P

Original languageEnglish
Pages (from-to)774-780
Number of pages7
JournalJournal of Pediatric Hematology/Oncology
Issue number12
Publication statusPublished - Dec 2006



  • Cancer risk after treatment
  • Chemotherapy
  • Osteosarcoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Pediatrics, Perinatology, and Child Health

Cite this